About: Inhibitors of SARS-CoV Entry - Identification using an Internally-Controlled Dual Envelope Pseudovirion Assay

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Inhibitors of SARS-CoV Entry - Identification using an Internally-Controlled Dual Envelope Pseudovirion Assay Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Inhibitors of SARS-CoV Entry - Identification using an Internally-Controlled Dual Envelope Pseudovirion Assay
Creator	Lu, Kai Simmons, Graham Zhou, Yanchen Agudelo, Juliet Hansell, Elizabeth »more»
source	Elsevier; Medline; PMC
abstract	Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) emerged as the causal agent of an endemic atypical pneumonia, infecting thousands of people worldwide. Although a number of promising potential vaccines and therapeutic agents for SARS-CoV have been described, no effective antiviral drug against SARS-CoV is currently available. The intricate, sequential nature of the viral entry process provides multiple valid targets for drug development. Here, we describe a rapid and safe cell-based high-throughput screening system, Dual Envelope Pseudovirion (DEP) Assay, for specifically screening inhibitors of viral entry. The assay system employs a novel dual envelope strategy, using lentiviral pseudovirions as targets whose entry is driven by the SARS-CoV Spike glycoprotein. A second, unrelated viral envelope is used as an internal control to reduce the number of false positives. As an example of the power of this assay a class of inhibitors is reported with the potential to inhibit SARS-CoV at two steps of the replication cycle, viral entry and particle assembly. This assay system can be easily adapted to screen entry inhibitors against other viruses with the careful selection of matching partner virus envelopes.
has issue date	2011-11-01(xsd:dateTime)
bibo:doi	10.1016/j.antiviral.2011.07.016
bibo:pmid	21820471
has license	bronze-oa
sha1sum (hex)	28ee77d84e0753d32bbb58190d2d9e76f8856a30
schema:url	https://doi.org/10.1016/j.antiviral.2011.07.016
resource representing a document's title	Inhibitors of SARS-CoV Entry - Identification using an Internally-Controlled Dual Envelope Pseudovirion Assay
has PubMed Central identifier	PMC3205982
has PubMed identifier	21820471
schema:publication	Antiviral Research
resource representing a document's body	covid:28ee77d84e0753d32bbb58190d2d9e76f8856a30#body_text
is schema:about of	named entity 'SARS-COV' named entity 'INFECTING' named entity 'PROVIDES' named entity 'CORONAVIRUS' named entity 'ASSOCIATED' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software